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Summary
Objectives: A cluster- randomized trial of home- based care using primary- care re-
sources for people with epilepsy has been set up to optimize epilepsy care in resource- 
limited communities in low- and middle- income countries. The primary aim is to 
determine whether treatment adherence to antiepileptic drugs is better with home- 
based care or with routine clinic- based care. The secondary aims are to compare the 
effects of the two care pathways on seizure control and quality of life.
Methods: The home- based intervention comprises epilepsy medication provision, 
adherence reinforcement, and epilepsy self- management and stigma management 
guidance provided by an auxiliary nurse- midwife equivalent. The experimental 
group will be compared to a routine clinic- based care group using a cluster- 
randomized design in which the unit of analysis is a cluster of 10 people with epi-
lepsy residing in an area cared for by a single accredited government grass- roots 
health care worker. The primary outcome is treatment adherence as measured by 
monthly tablet counts supplemented by two self- completed questionnaires. The sec-
ondary outcomes include monthly seizure frequency, time to first seizure (in days) 
after enrollment, proportion of patients experiencing seizure freedom for the duration 
of the study, and quality of life measured by the “Personal Impact of Epilepsy Scale,” 
all assessed by an independent study nurse.
Results: The screening phase and neurologic evaluations and randomizations have 
been recently completed and follow- up is underway.
Significance: The results of the trial are likely to have substantial bearing on the 
development of governmental policies and strategies to provide coverage and care 
for patients with epilepsy in resource- limited countries.
K E Y W O R D S
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1 |  INTRODUCTION
Epilepsy affects over more than 50 million people worldwide 
and the majority of those affected live in low- and middle- 
income countries (LMICs).1 Many persons with epilepsy 
in LMICs are deprived of appropriate treatment and sup-
port.1–4 The provision of suitable care to such large numbers 
of people with epilepsy is challenging. The World Health 
Organization (WHO) envisages epilepsy care as a joint re-
sponsibility between primary and secondary health care 
providers.1 In high- income countries, the main tasks of sec-
ondary care are to provide diagnostic and investigative ser-
vices on a consultation basis, institute treatment changes, and 
provide counseling and follow- up when appropriate. Primary 
care providers are delegated the tasks of case finding, refer-
ral to secondary care and follow- up on the advice provided. 
Conversely, the provision of epilepsy care in LMICs using 
a similar model is problematic because of barriers on the 
supply side (eg, unavailable antiepileptic drugs [AEDs], 
long distances to health facilities, and insufficient expertise 
to treat epilepsy), as well as those on the demand side (eg, 
treatment costs, cultural beliefs regarding epilepsy, stigma, 
and faith in traditional treatment providers).5 The paucity 
of trained physicians is one of reasons for the poor stand-
ards of care for epilepsy in LMICs. For example, there are 
an estimated 8- 12 million people with epilepsy in India.6–8 
Applying the yardstick of one neurologist for 100 000 peo-
ple would require at least 8000 neurologists.9,10 The WHO 
estimates, however, a median of 0.07 neurologists/100 000 
population in South/Southeast Asia.11 Hence, the number of 
neurologists available for epilepsy care falls short of the re-
quired number and, consequently, epilepsy care has defaulted 
to primary care providers in this region.
The WHO recently asked member states to introduce and 
implement national epilepsy programs to reduce the gap in 
provision of care, particularly in poor and remote regions, 
and to integrate epilepsy management into primary care.12 
The aim is to achieve a substantial reduction in the magnitude 
of the treatment gap in LMICs by overcoming some of the 
existing barriers.6–8
Home- based care for epilepsy delivered by primary care 
personnel might overcome some of the barriers, by providing 
regular, cost- free AEDs, eliminating the “distance to health 
facility,” and providing knowledge and guidance to mitigate 
stigma and false beliefs, and to aid self- management. India is 
ideally suited for testing a care model integrating specialist 
neurologic expertise within the existing primary care infra-
structure. There are now more than 2000 qualified neurol-
ogists in the country, albeit insufficient to provide epilepsy 
care but enough to guide and counsel epilepsy care delivered 
by primary care providers. There is also a vast resource of 
personnel and operational infrastructure supporting primary 
care across the country. Hence, we have set up a pragmatic, 
community- based, cluster- randomized trial of home- based 
epilepsy care delivery by primary care health providers 
under the supervision of neurologists. The trial is now on-
going with enrollment and randomization completed. Herein 
we report on the aims, recruitment and interventional proto-
cols, and the progress so far.
2 |  MATERIALS AND METHODS
2.1 | Aims
We are aiming to determine whether a home- based intervention 
comprising provision of AEDs and health education emphasiz-
ing epilepsy self- and stigma- management improves treatment 
adherence compared with the usual clinic- based epilepsy care 
in the community. We will also estimate the impact of home- 
based care on seizure control and quality of life. Additional ob-
jectives include identification of barriers in the implementation 
of primary care for epilepsy in resource- limited settings.
2.2 | Setting of trial
The trial has been initiated in the urban and semi- urban rural 
areas of the Ludhiana district with an area of 3767 km2 and 
an estimated population of 1.9 million (2011 Census India).13 
Approximately 80% of the population is literate and 30% are 
manual workers. The Government Health Department has di-
vided the urban and peri- urban rural areas into nine zones to 
facilitate immunization coverage (Figure 1A).
2.3 | Screening for potential subjects* 
The cluster sampling approach for evaluating vaccination 
coverage was used to identify individuals with epilepsy in 
Key Points
• The treatment gap for epilepsy is wide in low- and 
middle-income countries
• Despite the provision of drugs, many people with 
epilepsy abandon treatment in the long term
• A pragmatic, population-based, cluster-rand-
omized trial of home-based provision of medica-
tions by primary-care personnel has been set up
• We aim to determine the impact of home-based 
care on treatment adherence, seizure control, and 
quality of life
• We hope that the trial results will provide direc-
tion on policy regarding epilepsy care provision in 
low- and middle-income countries
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the community.14 Clusters were selected from areas with 
lower sociodemographic indices, for which grassroots 
community health workers (Accredited Social Health 
Activists [ASHAs]) were available and willing to assist.15 
A prevalence of 10 cases of epilepsy/1000 population was 
inferred from prevalence surveys in India, to which a 50% 
inflation was factored in to account for locked households, 
and for refusal to participate in screening or to enroll in 
the trial.16–18 A decision was made to screen about 2000 
people in each screening cluster. This amounted to 2- 3 
screening- clusters per immunization zone and 24 clusters 
in all (Figure 1A).
Beginning on December 7. 2017, study personnel accom-
panied by ASHAs visited door- to- door within each screening 
cluster using detailed geographic information system maps 
with household numbers superimposed on Google maps. 
They used a screening questionnaire, previously employed 
in Ecuador, and translated and validated earlier in this com-
munity (estimated sensitivity, 0.83; specificity, 0.84; predic-
tive values, positive—59.76% and negative—60.48%).18,19 
F I G U R E  1  A, Map of the study 
area with division in to nine immunization 
zones. The primary health centers, district 
hospitals, and two private medical college 
hospitals are also mapped. B, Map of a 
randomly chosen screening cluster depicting 
the progress of door- to- door screening
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Subjects were classified either as “suspected epilepsy cases” 
or “screened negative for epilepsy” (Table S1). Screening 
started from a randomly chosen dwelling unit and proceeded 
in an orderly fashion, advancing to consecutive houses along a 
street and then to the adjoining street (Figure 1B). Inventories 
for locked, leased, and those households for which no offi-
cial records exist in the municipality, as well as of all family 
members in any given unit, were maintained. Locked house-
holds were revisited twice before excluding them.
2.4 | Geospatial mapping*
The health department provided us with a current list of 
health facilities. The locations of these health centers were 
mapped using a global positioning system (GPS). Ward and 
immunization zone boundaries of the area were overlaid on 
the location map using ArcGIS 10.4 (ESRI, Redlands, CA). 
World View- II satellite data (spatial resolution: 0.5 m) was 
also used to map individual properties. Maps of each cluster 
thus generated were reviewed with designated ASHAs, GIS 
experts, and field workers prior to commencing screening. 
Suspected and enrolled cases were flagged on GIS maps of 
each cluster to assist follow- up during home- based care.
2.5 | Neurologic evaluations and treatment 
planning*
Suspected cases from the screening program were invited 
for neurologic assessments by study- team neurologists (two 
adult and one pediatric) with expertise in epilepsy. They 
were assessed on a conservative basis with a minimum of 
a 1- hour awake and sleep electroencephalography (EEG) 
(Nihon Kohden, Japan) and magnetic resonance imaging 
(MRI) (3 Tesla; Siemens, Germany) at a local academic 
hospital. Subsequently, treatment plans were generated and 
the choice of drugs and the manner of initiation were left to 
the judgment of the neurologists. AEDs used were restricted 
to those on the essential drug list with two exceptions: (a) 
subjects with active epilepsy who were seizure- free prior to 
enrollment on AED treatment are maintained on the same 
medication/s and (b) valproate use is avoided, when possible, 
in women in the reproductive age group.20,21
2.6 | Sample size*
An adherence rate of 60% in the clinic- based arm was as-
sumed from previous Indian reports.22,23 Good adherence was 
assumed when the number of remainder pills counted during 
monthly assessments by the study nurse was within ±2 days’ 
stock.24 The sample size (n) was calculated to compare the pro-
portion of patients with good adherence in an individual- level 
randomized- controlled trial to improve adherence rates from 
60% to 80% with power of 0.8 and a significance level of 0.05. 
In the absence of data on variance of adherence, an intracluster 
coefficient (ICC) (ρ) of 0.05 was initially assumed. The ICC has 
since been reset on the basis of data accrued during the interim 
(3 months after recruitment of 10 clusters) analysis to 0.000001 
(95% confidence intervals, <0.000001- 0.021). The number of 
individuals in each cluster (m) was fixed at 10.
The design effect (D) for a parallel, cluster- randomized 
trial was calculated using the formula:
D = 1 + (m − 1)ρ,25,26
where m = number of individuals in a cluster.
The number of clusters with 10 subjects each for a parallel 
arm, cluster randomized trial (nCRT) was calculated using the 
following formula:
nCRT = D × n/m.25
The estimated number of subjects in each arm (n) was 91. 
To make up for an anticipated attrition rate of 30%, the total 
number of recruited subjects was fixed at 240 and number of 
clusters recruited (nCRT) set to 24.
2.7 | Trial recruitment and randomization*
After neurologic assessments, subjects over 1- year old with ac-
tive epilepsy were invited to enroll in the trial regardless of prior 
treatment status (see Box S1, for operational definitions). People 
with febrile seizures, neonatal seizures, single seizures not ful-
filling the current operational definition for epilepsy, and acute 
symptomatic seizures associated with head injury, stroke, and 
toxic, metabolic, and acute infective conditions were excluded.27
The randomization- cluster (as distinct from the screening- 
cluster) unit was fixed at 10 subjects with confirmed active 
epilepsy derived from a screening- cluster (Figure 2). Clusters 
were randomized as soon as they were assembled according to 
a computer- generated, simple randomization scheme to either 
home- based care or usual clinic- based care. The randomization 
list was made previously made and is kept by a Randomization 
Officer (S.S.) not involved in recruitment or evaluations, who 
disclosed allocation only on completion of cluster assembly.
2.8 | Interventional package and control 
procedures# 
Subjects in the clinic- based arm (n = 120; age range 1- 80 years) 
are asked to attend monthly clinics at the Government District 
Hospital for review visits and drug dispensing. Those in the 
other arm (n = 120; age range 1- 67 years) receive an inter-
ventional package comprising the following: (a) delivery of 
AEDs; (b) education and counseling about self- management, 
social functioning, and stigma abrogation; and (c) adherence 
monitoring; all provided at home on a monthly basis by study 
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personnel with qualifications equivalent to auxiliary nurse 
midwives (ANMs). During the first home visit, the study 
purpose is explained, and information about drugs, including 
frequency and timings of drug taking, are provided. A compre-
hensive brochure, a seizure diary, and prescription record are 
also supplied. During subsequent monthly visits, study person-
nel hold continued discussions regarding self- management; 
impart psychosocial education pertaining to schooling, mar-
riage, and employment; inquire about medication side- effects; 
verify seizure diaries; and supply the scheduled stock of AEDs.
Records of home visits are reviewed at monthly meet-
ings with the study neurologists who make changes in 
the treatment plan based on reports of seizure control, 
side- effects, and other circumstances, as necessary. Any 
changes in treatment plan are implemented by unsched-
uled home visits. Interim visits to the study neurologists 
take place for people with inadequate seizure control, un-
acceptable side- effects, or pregnancy in women with epi-
lepsy. Likewise, subjects in the clinic- based arm can make 
ad hoc clinic visits or be referred to the study neurologists 
if they have inadequate seizure control, side- effects, or 
pregnancy. Medications are provided cost- free to subjects 
in both arms. Pediatric formulations are used for children 
<12 years of age.
2.9 | Outcomes#
The primary outcome of the trial is adherence, appraised at 
monthly intervals by pill counts and vernacular versions of 
the Self- Reporting Medication- Taking Scale (SRMS) and 
Brief Medication Questionnaire (BMQ).28,29 Secondary out-
comes include quality of life appraisal by the Personal Impact 
of Epilepsy (PIES) scale and several seizure- related parame-
ters including monthly seizure frequency, time to first seizure 
(in days) after enrollment, and the proportion of subjects ex-
periencing seizure freedom for the duration of the study.24,30 
Outcomes are assessed independently by a study nurse, who 
not involved in recruitment or dispensing and trained in the 
use of the instruments described below.
2.10 | Instruments#
2.10.1 | Medication adherence
Pill counts
Adherence is evaluated by counting residual dosage units of 
each AED dispensed during the preceding month and is as-
sumed to be good when the number of dosage units consumed 
are within ±2 days of a month's prescribed use.24 When more 
F I G U R E  2  Trial flow chart depicting screening, evaluation, randomization, and assessments
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or fewer than 2 days of a month's use of dosage units are 
counted, adherence is deemed to be poor. When pills are 
not available (eg, destroyed, misplaced, or lost) for counting 
during the assessment visits or when subjects use pills from 
stocks other than those provided by the study personnel, the 
pill counts are classified as indeterminate.
Questionnaire- based measures
The SRMS is a 4- item scale to assess medication nonadher-
ence.28 It asks about different modes of medication omis-
sion associated with forgetfulness, carelessness, and stopping 
medications when feeling better or when feeling worse (due to 
side- effects of medications or failure to control seizures). The 
items in the questionnaire are presented in a negative structure 
to eliminate “yes bias.”31 The BMQ is a screening question-
naire to identify nonadherence or barriers to adherence.29 It in-
cludes three screening questions that measure different aspects 
of medication- taking behavior. A positive regimen screen indi-
cates potential nonadherence, a positive belief screen discloses 
beliefs that might be linked to nonadherence by inquiring about 
the effectiveness or bothersomeness of the medication/s and 
the recall screen characterizes barriers to recall (eg, due to the 
complexity of the regimen). Both scales are administered to the 
subjects or their parents (for children <18 years).
2.10.2 | Quality of life
We selected the PIES to measure quality of life as it ap-
praises seizure burden, AED side- effects, and mood and cog-
nition in addition to overall quality of life on a Likert scale.30 
Moreover, it can be administered to family members in case 
of children and illiterate subjects.
2.10.3 | Ancillary appraisals
To document fully the impact of the intervention; addi-
tional evaluations, for example, Epilepsy Self- management 
Scale, Kilifi Epilepsy Stigma Scale, and the Kilifi Epilepsy 
Beliefs and Attitudes Scales are planned.32–35 Records are 
also maintained of interim visits in the home- based arm and 
ad hoc clinic visits and referrals in the clinic- based arm. An 
economic analysis of the intervention, based on governmen-
tal and societal perspectives, is also underway in a parallel 
study. The analytic horizon will be for the trial period.
2.10.4 | Safety assessments and monitoring
Spontaneous accounts of AED adverse events are recorded 
at each encounter and discussed at monthly study team meet-
ings. Emphasis is placed on serious adverse events, preg-
nancy, and suicidality reporting, and standard protocols are 
followed to deal with the situations. Finally, a structured ad-
verse event inventory is administered once every 6 months.36
All scales have been translated to the vernacular lan-
guage (Punjabi) by two multilingual translators unconnected 
to the study team, followed by correspondence assess-
ment.28–30,32–36 Vernacular versions have then been back- 
translated to the English language and compared with the 
original English versions. The translated versions have been 
administered to 15 people with epilepsy drawn from the out-
patient clinic to verify linguistic comprehension and applica-
bility of the items. Lastly, the Likert scale has been adapted to 
a one Indian Rupee (=100 paisa) monetary scale (Figure S1) 
to quantify responses to the questions in a manner acceptable 
to respondents with poor literacy.
2.11 | Assessment schedules#
The duration of the trial will be for 24 months. The study 
nurse records outcomes on an android tablet (Samsung Galaxy 
Tablet ver. 7.0 each month. The data are then downloaded to 
a central server. Pill counts are performed and the SRMS and 
BMQ scales are administered every month (Figure 3).28,29 
The adverse effects profile questionnaire is administered once 
in 3 months, PIES once in 6 months, and the Epilepsy self- 
management, Kilifi stigma, and Kilifi Beliefs and Attitudes 
scales are administered in the beginning, mid- way, and at the 
end of the trial.30,32–35 The data are password protected and in 
the keeping of the study statistician (N.B.), who validates a 
random 10 from paper records every month.
2.12 | Statistical analysis#
Baseline, individual- level analysis will compare sociodemo-
graphic characteristics including age, gender, socioeconomic 
status, duration of epilepsy and prior seizure frequency in 
the two arms. The Revised Kuppuswamy scale corrected for 
monetary inflation, which records education and occupation 
of the head of the family and family income, was used to es-
timate the socioeconomic status.37 The first interim analysis 
was planned 3 months after recruitment of 10 clusters. The 
purpose of this analysis was to recalculate the ICC accord-
ing to the primary outcome measure and hence reestimate the 
sample size and to examine the psychometric properties of 
SRMS, BMQ, and the PIES instruments. A second interim 
analysis is planned for 12 months after recruitment of the 
final cluster to assess attrition rates in the two groups. The 
analysis would require premature stopping of the trial if the 
attrition rate in the clinic- based arm exceeds 40%.38
In the final analysis after completion of all monthly as-
sessments, cluster level summaries for each of the primary 
and secondary outcomes will be calculated (Figure 3). Point 
estimates (and their confidence intervals) of the intervention 
effect will be obtained from the cluster- level summaries using 
the ‘t’ distribution (Table 1).26 Hypothesis testing will use the 
unpaired t test for cluster level summaries in each arm. Finally, 
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the effect of covariates including age, gender, socioeconomic 
status, duration of epilepsy, prior seizure control, distance 
from the District Hospital, within individual correlation over 
time (to account for a repeated measures design for adherence) 
will be examined in individual- level, random- effects, logistic- 
regression models. The intervention effect will not be entered 
into the model at this stage. The residuals thus generated 
would constitute the summary measure for each cluster, which 
will then be compared between the two arms using the t test.26
Attrition rates and missing data for the outcome measures 
will be described. In the clinic- based arm, baseline data on 
subjects who withdraw after enrollment will be compared 
with those continuing the trial.38 An earlier observation car-
ried forward approach will be used to handle missing data 
during statistical modeling of adherence.39 Missing data will 
not be imputed in the analysis of other outcomes but various 
sensitivity analyses under random, as well as not- at- random 
assumptions, will be performed. Stata version 15.1 (Stata 
Corp LLC, TX) will be used for the statistical analysis.
2.13 | Ethical considerations and 
protocol standards
The trial was approved by the local institutional ethics com-
mittee, overseen by an independent, three- member Data 
Monitoring and Safety Committee, and is registered with the 
Clinical Trials Registry of India (ref/2017/09/015380). The 
data sharing policy is available at http://researchatdmch.com/
study-design-paper-gs/. Informed consents are recorded from 
all subjects older than18 years of age and from parent/legally 
acceptable representative in the case of children (in addi-
tion to oral assent from children 7- 11 years of age and writ-
ten assent from children over 12 years of age).The research 
methods and reporting follow Consolidated Standards of 
Reporting Trials criteria for extension to cluster randomized 
trials and for pragmatic trials.40,41
3 |  DISCUSSION
Home- based care for epilepsy with primary care workers as 
the point of contact is a feasible option. Potential benefits 
include provision of care in the home environment using 
community resources in the setting of poor specialist care 
provision, engagement of family members as stakehold-
ers, and reduction in direct non- medical and indirect costs 
of treatment (in the form of expenses incurred in traveling 
to clinics and wages lost). It is suited for those who find it 
difficult to travel (eg, elderly, those with physical disabil-
ity, and children). Repeated visits and counseling by health 
F I G U R E  3  Trial assessment schedules
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care workers may also improve adherence, as people often 
discontinue treatment either in frustration over side- effects 
or failure of medications to control seizures, or simply after 
experiencing seizure freedom.24 The approach has been un-
dertaken before in underserved communities but has not been 
formally tested in a randomized- controlled trial.42
We chose to test home- based provision of medications 
and care and counseling by community health care workers 
against the usual clinic- based care in a cluster- randomized 
trial with a pragmatic design. The initial screening cluster 
size was fixed at 2000, as this was the population covered 
by one ASHA, a voluntary foundation- level social health 
worker. The ASHAs reside in the clusters covered by them 
and are hence well- informed about the health status of the 
residents. This helps in identifying potential participants, es-
pecially in the context of epilepsy, a stigmatized condition, 
which is often not disclosed during screening campaigns.43 
The randomization- cluster unit comprised people with ep-
ilepsy in the screening cluster and was adopted mainly for 
logistic convenience and acceptability.26 Another justifica-
tion for cluster- randomization was to prevent contamination 
of the counseling effects.44 Consonant with the cluster size 
implemented for screening, the expected yield of potential 
participants with confirmed epilepsy who might consent to 
randomization was 10.
Medication adherence was selected over seizure control 
or quality of life as a primary outcome in consideration of 
the short duration of the trial. We thought that repeated home 
visits and counseling would directly impact medication ad-
herence, epilepsy self- management, and coping with stigma. 
Seizure control might be a downstream effect of the interven-
tion and, additionally, might be influenced by variables such 
as the characteristics of epilepsy and AEDs administered. 
Even so, average monthly seizure frequency, time to the first 
seizure after randomization, and the proportion of subjects in 
either arm who experienced seizure freedom throughout the 
trial period were chosen as (clinical) secondary outcomes. 
To incorporate a participant- reported outcome, we chose the 
PIES, a new instrument that measures seizure severity and 
frequency, AED- related adverse effects, and mood and cog-
nition in addition to overall quality of life.30 This was pre-
ferred over existing generic and epilepsy- specific quality of 
life scales, as it can be administered across a range of age 
groups and to subjects and their family members, an import-
ant consideration in its applicability in people with poor liter-
acy.45–49 Limitations of the scale, however, included the scant 
experience with its use and the lack of an established clini-
cally meaningful difference associated with its use.
A number of measures for evaluating medication ad-
herence have been proposed. Some, such as the electronic 
medication monitoring systems or serial serum AED level 
measurements, are highly specific and sensitive mea-
sures, but cost and impracticalities in a limited- resources 
setting precluded their use.50,51 We opted for pill count as 
the primary measure of adherence, supplemented by two 
participant- completed questionnaires because of its antici-
pated reliability and consistency of measurement across dif-
ferent age groups.51–53 Monitoring pill counts also presents 
unique challenges, as illustrated by a number of situations in 
which pill counts were found to be indeterminate, for exam-
ple, due to locked houses during assessments, misplaced or 
lost pills, and contamination with medications acquired by 
subjects from other sources.
Geographic information system mapping was used for the 
following: (a) to aid the screening activity by mapping out 
households within each cluster; (b) to determine geographic 
correlates including spatial clustering of the epilepsy cases 
identified in the community survey; and (c) to aid in the anal-
ysis of the distance factor associated with treatment- seeking 
behavior of the control group.54–56
Screening, identification, and ascertainment of epilepsy are 
important components of any community- oriented epilepsy 
care program in LMICs. The present report emphasizes the 
interventional component as distinct from screening and case 
ascertainment. Other limitations include the use of simulated 
field staff, who, despite similar educational level and expe-
rience as existing community health workers, were commis-
sioned solely for this project. We do not know how effective it 
is to delegate epilepsy care to the existing community health 
workers in India, initially hired mainly for mother and child 
care and later burdened with a variety of health- related tasks.57 
The limited geographic scope of the trial also precludes gener-
alizability, and we do not know how effective the arrangement 
would be in remotely located rural areas in the country.
In the context of providing universal care for epilepsy, sev-
eral issues including allocation of funds, augmenting the sup-
ply side, and dealing with competing private care need to be 
addressed. Our initial experience illustrates some of the chal-
lenges faced in undertaking a randomized trial in an impov-
erished community with poor disease- and treatment- literacy. 
Enrollment following the screening phase was initially mod-
est, perhaps due to poor faith in the public health system, but 
later improved. We have, and will continue, to cope with heavy 
relocation of trial subjects within and outside the community, 
largely for economic reasons. In addition, it is particularly 
challenging to sustain medication adherence in the long term 
for a chronic disorder such as epilepsy in a subject population 
that is heavily stigmatized, has poor treatment- literacy owing 
to low levels of education and fragmentary access to channels 
of public communication, and has continuing faith in compet-
ing health care systems, for example, faith healers.58,59
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